Bristol-Myers Squibb Company (BMY)
NYSE: BMY · Real-Time Price · USD
58.70
-0.49 (-0.83%)
Mar 26, 2025, 9:59 AM EDT - Market open
BMY Revenue
In the year 2024, Bristol-Myers Squibb Company had annual revenue of $48.30B with 7.32% growth. Bristol-Myers Squibb Company had revenue of $12.34B in the quarter ending December 31, 2024, with 7.54% growth.
Revenue (ttm)
$48.30B
Revenue Growth
+7.32%
P/S Ratio
2.48
Revenue / Employee
$1,416,422
Employees
34,100
Market Cap
119.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 48.30B | 3.29B | 7.32% |
Dec 31, 2023 | 45.01B | -1.15B | -2.50% |
Dec 31, 2022 | 46.16B | -226.00M | -0.49% |
Dec 31, 2021 | 46.39B | 3.87B | 9.09% |
Dec 31, 2020 | 42.52B | 16.37B | 62.62% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BMY News
- 23 hours ago - Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold - Seeking Alpha
- 2 days ago - Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Benzinga
- 5 days ago - Merck Vs. Bristol-Myers Squibb: Which Pharma Stock Should You Buy - Seeking Alpha
- 7 days ago - 10 Undervalued Dividend Growth Stocks: March 2025 - Seeking Alpha
- 7 days ago - Bristol-Myers Squibb: Why I'm Still Bullish - Seeking Alpha
- 11 days ago - 2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT - Business Wire
- 12 days ago - Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma - Business Wire
- 13 days ago - Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025 - Business Wire